Morningstar

Telix Pharmaceuticals Ltd Ordinary Shares TLX

Stock XASX Rating as of Oct 23, 2026

News

Telix Reports Third Quarter 2026 Financial Performance

GlobeNewswire Oct 20, 2026, 10:10:12 PM
Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.

GlobeNewswire Oct 19, 2026, 5:30:00 AM
Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care

GlobeNewswire Oct 9, 2026, 11:45:00 AM
First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)

GlobeNewswire Oct 6, 2026, 10:30:00 AM
Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse

GlobeNewswire Sep 21, 2026, 12:55:38 AM
FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara

GlobeNewswire Sep 14, 2026, 10:30:00 AM
Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewswire Sep 9, 2026, 10:30:00 AM
Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway

GlobeNewswire Sep 1, 2026, 10:18:49 PM
Telix Appoints David Gill as Chair

GlobeNewswire Aug 31, 2026, 10:21:00 PM
Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline

GlobeNewswire Aug 20, 2026, 12:32:23 AM
Telix to Host R&D Day in New York City on September 22, 2026

GlobeNewswire Aug 5, 2026, 11:00:00 AM
Telix H1 2026 Results: Investor Webcast Notification

GlobeNewswire Jul 30, 2026, 10:37:53 PM

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.